One dose of gene-editing drug reduces bad cholesterol by 62% in small trialArs Technica
A single dose of Lilly’s PCSK9 base editor, VERVE-102, reduced PCSK9 by 88% and LDL-C by 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemiainvestors.lilly.com
One-time experimental treatment could control cholesterol for lifetime magazine
Heart disease prevention? Scientists believe this may be possible.the new York Times
A gene therapy reduced cholesterol in early trial results. It has a Philly backstory.inquirer.com
